Acknowledgement
This Research was supported by Duksung Women's University Research Grant 2019. The authors thank Dr. Hao Jin (Duksung Innovative Drug Center) for helpful discussion.
References
- Curado MP (2011) Breast cancer in the world: Incidence and mortality. Salud Publica de Mex 53:372-384. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDREVISTA=79&IDARTICULO=31619&IDPUBLICACION=3422
- Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113-126. https://doi.org/10.1111/joim.12084
- Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ, Townsend AR (2019) Druggable molecular targets for the treatment of triple negative breast cancer. J Breast Cancer 22:341-361. https://doi.org/10.4048/jbc.2019.22.e39
- Shi M, Liu D, Duan H, Shen B, Guo N (2010) Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 29:785-799. https://doi.org/10.1007/s10555-010-9265-9
- Cleere DW (2010) Triple-negative breast cancer: a clinical update. Community Oncol 7:203-211. https://doi.org/10.1016/s1548-5315(11)70394-1
- Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368-1383. https://doi.org/10.1002/1097-0142(19930215)71:4%3c1368::aid-cncr2820710432%3e3.0.co;2-l
- Liotta LA, Trygguason K, Garbisa S, Hart I, Foltz CM, Shafe S (1980) Metastasis potential correlate with enzymatic degradation of basement membrane collagen. Nature 284:67-68. https://doi.org/10.1038/284067a0
- Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-433. https://doi.org/10.1006/scbi.2000.0379
- Brungs D, Chen J, Aghmesheh M, Vine KL, Becker TM, Carolan MG, Ranson M (2017) The urokinase plasminogen activation system in gastroesophageal cancer: a systematic review and meta-analysis. Oncotarget 8:23099-23109. https://doi.org/10.18632/oncotarget.15485
- Lijnen HR (2002) Matrix metalloproteinases and cellular fbrinolytic activity. Biochem. (Moscow) 67:92-98. https://doi.org/10.1023/a:1013908332232
- Wilkins-Port CE, Higgins SP, Higgins CE, Kobori-Hotchkiss I, Higgins PJ (2012) Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: functional interactions between the serine protease and matrix metalloproteinase cascades. Biochem Res Int 2012:454368. https://doi.org/10.1155/2012/454368
- Ulisse S, Baldini E, Bocchini S, D'Armiento M (2008) The encyclopedia of cancer. In: Schwab M (ed) Plasminogen activating system, 2009th edn. Springer, Berlin, Heidelberg, New York, pp 134-137
- Jannicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofer H, Graef H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208. https://doi.org/10.1007/bf01833260
- Praus M, Collen D, Gerard RD (2002) Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fbrosarcoma cell metastasis. Inl J Cancer 102:584-591. https://doi.org/10.1002/ijc.10767
- Lin SR, Fu YS, Tsai MJ, Cheng H, Weng CF (2017) Natural compounds from herbs that can potentially execute as autophagy inducers for cancer therapy. Int J Mol Sci 18:1412. https://doi.org/10.3390/ijms18071412
- Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of diferent cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199-225. https://doi.org/10.1016/j.canlet.2008.03.009
- Kim MS, Kang HJ, Moon A (2001) Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res 24:349-354. https://doi.org/10.1007/bf02975105
- Zhou X, Jiao D, Dou M, Zhang W et al (2020) Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression. J Cell Mol Med 24:10648-10662. https://doi.org/10.1111/jcmm.15683
- Shindikar A, Singh A, Nobre M, Kirolikar S (2016) Curcumin and resveratrol as promising natural remedies with nanomedicine approach for the efective treatment of triple negative breast cancer. J Oncol 2016:9750785. https://doi.org/10.1155/2016/9750785
- Adams BK, Cai J, Armstrong J, Herold M et al (2005) EF24, a novel synthetic curcumin analog, induces apoptosisin cancer cells via a redox-dependent mechanism. Anticancer Drugs 16:263-275. https://doi.org/10.1097/00001813-200503000-00005
- Zhang L, Qiang P, Yu J, Miao Y et al (2019) Identifcation of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor efect against non-small cell lung cancer. Autophagy 15:391-406. https://doi.org/10.1080/15548627.2018.1511503
- Guan F, Ding Y, Zhang Y, Zhou Y, Li M, Wang C (2016) Curcumin suppresses proliferation and migration of MDA-MB-231breast cancer cells through autophagy-dependent Akt degradation. PLoS ONE 11:e0146553. https://doi.org/10.1371/journal.pone.0146553
- Wang K, Zhang C, Bao J, Jia X et al (2016) Synergistic chemopreventive efects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death. Sci Rep 6:26064. https://doi.org/10.1038/srep26064
- Jiang P, Mizushima N (2014) Autophagy and human diseases. Cell Res 24:69-79. https://doi.org/10.1038/cr.2013.161
- Lefort S et al (2014) Inhibition of autophagy as a new means of improving chemotherapy efciency in high-LC3B triple-negative breast cancers. Autophagy 10:2122-2142. https://doi.org/10.4161/15548627.2014.981788
- Wang MC et al (2015) Autophagic regulation of cell growth by altered expression of Beclin 1 in triple-negative breast cancer. Int J Clin Exp Med 8:7049-7058 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509187/
- Shin I, Kim S, Song H, Kim HRC, Moon A (2005) H-Ras-specifc activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 280:14675-14683. https://doi.org/10.1074/jbc.m411625200
- Koh M, Woo Y, Valiathan RR, Jung HY et al (2015) Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition. Int J Cancer 136:E508-E520. https://doi.org/10.1002/ijc.29154
- Boulares AH, Yakovlev AG, Ivanova V, Stoica BA et al (1999) Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274:22932-22940. https://doi.org/10.1074/jbc.274.33.22932
- Jin H, Choi H, Kim ES, Lee HH, Cho H, Moon A (2021) Natural killer cells inhibit breast cancer cell invasion through down-regulation of urokinase-type plasminogen activator. Oncol Rep 45:299-308. https://doi.org/10.3892/or.2020.7840
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srivinas PS (1998) Infuence ofpiperine on the in animals pharmacokinetics of curcumin and humanvolunteers. Planta Med 64:353-356. https://doi.org/10.1055/s-2006-957450
- Jitariu AA, Cimpean AM, Ribatti D, Raica M (2017) Triple negative breast cancer: the kiss of death. Oncotarget 8:46652-46662. https://doi.org/10.18632/oncotarget.16938
- Sotiriou C, Neo SY, McShane LM, Korn EL et al (2003) Breast cancer classifcation and prognosis based on gene expression profles from a population-based study. PNAS 100:10393-10398. https://doi.org/10.1073/pnas.1732912100
- Kaplan HG, Malmgren JA (2008) Impact of triple negative phenotype on breast cancer prognosis. Breast J 14:456-463. https://doi.org/10.1111/j.1524-4741.2008.00622.x
- Stetler-Stenvenson WG (1990) Type IV collagenase in tumor invasion and metastasis. Cancer Metastasis Rev 9:289-303. https://doi.org/10.1007/BF00049520
- Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14:297-307. https://doi.org/10.1007/BF00053903
- Mauro CD, Pesapane A, Formisano L, Rosa R et al (2017) Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep 7:9388. https://doi.org/10.1038/s41598-017-10062-1
- Mahmood N, Mihalcioiu C, Rabbani SA (2018) Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front Oncol 8:24. https://doi.org/10.3389/fonc.2018.00024
- Wang L, Madigan MC, Chen H, Liu F et al (2009) Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol 114:265-272. https://doi.org/10.1016/j.ygyno.2009.04.031
- Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K (2006) Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 28:807-814. https://doi.org/10.3892/ijo.28.4.807
- Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA (2002) Regulation of DNA methylation in human breast cancer: efect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 277:41571-41579. https://doi.org/10.1074/jbc.M201864200
- Rau JC, Beaulieu LM, Huntington JA, Church FC (2007) Serpins in thrombosis, hemostasis and fbrinolysis. J Thromb Haemost 5:102-115. https://doi.org/10.1111/j.1538-7836.2007.02516.x
- Paramita P, Wardhani BW, Wanandi SI, Louisa M (2018) Curcumin for the prevention of ephithelial-mesenchymal transition in endoxifen-treated MCF-7 breast cancer cells. Asian Pac J Cancer Prev 19:1243-1249. https://doi.org/10.22034/APJCP.2018.19.5.1243
- Eddy AA, Fogo AB (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. JASN 17:2999-3012. https://doi.org/10.1681/ASN.2006050503
- Sof GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC (1996) Expression of plasminogen activator inhibitor type 1 in human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in athymic mouse model. J Clin Invest 96:2593-2600. https://doi.org/10.1172/JCI118323
- Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofer H, Janicke F, Graef H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb 78:285-296. https://doi.org/10.1055/s-0038-1657541